The Safety Profile of INVEGA HAFYERA™ Was Similar to That Seen With INVEGA TRINZA® (paliperidone palmitate) in the Double-blind Phase of the Study

Treatment-emergent Adverse Events (≥2%) During Noninferiority Study1

Chart depicting the frequency of treatment-emergent adverse events during the noninferiority trial

Patient Ratings of Injection-site Pain Were Mild

Patient Ratings of Injection-site Pain Were Mild, According to Visual Analog Scale1

Meter depicting patient ratings of injection-site pain

Investigator ratings of injection site:

Induration, redness and swelling were observed in 13% in the INVEGA HAFYERA™ group and 9% in the INVEGA TRINZA® group during the double-blind phase.1

REFERENCES: 1. INVEGA HAFYERA™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; August 2021. 2. Data on file. CSR. Janssen Pharmaceuticals, Inc., Titusville, NJ. 2020.